Ovarian Cancer Clinical Trials (as of June 2022) ENGOT-ov66/GEICO/A VB500-OC-004/ARRAVIVE Leading group: GEICO Clinical Trial Study: A phase 3, randomized, double-blind, adaptive, placebo/Paclitaxel-controlled study of AVB-S6-500 in combination with Paclitaxel in patients with Platinum-resistant recurrent ovarian cancer Planned number of patients: 300-500 Participating groups: MITO, MaNGO, GINECO, CEEGOG, HeGOG, BGOG, NCRI, PGOG, NOGGO ENGOT-ov65/MaNGO/KEYNOTE-B96 Leading group: MaNGO Clinical Trial Study: A phase 3, randomized, double-blind study of Pembrolizumab versus placebo in combination with Paclitaxel with or without Bevacizumab for the treatment of Platinum-resistant recurrent ovarian cancer Planned number of patients: 696 Participating groups: GINECO, BGOG, NSGO, NOGGO, ISGO, PGOG, NCRI-UK, TRSGO, DGOG ENGOT-ov64/NSGO-CTU/SOLERO Leading group: NSGO-CTU Clinical Trial Study: An early phase randomized trial of APX005M in BRCAwt patients with recurrent ovarian cancer Planned number of patients: 105 Participating groups: CEEGOG, BGOG, GEICO, SwissGO Planned start in 3Q 2022 ENGOT-ov63/GINECO/NIRVANA Leading group: GINECO Clinical Trial Study: NIRVANA (NIRaparib with or without beVacizumab in mAintenance after complete cytoreductioN in patients with ovArian cancer) Planned number of patients: 390 Participating groups: BGOG, MaNGO, GEICO, Gotic, KGOG ENGOT-ov62/NOGGO/N-PLUS Leading group: NOGGO Clinical Trial Study: NiraParib in optimaLly debUlked ovarian cancer patientS Planned number of patients: 536 Participating groups: TBA ENGOT-ov61/GEICO/EPIK-O Leading group: GEICO Clinical Trial Study: EPIK-O: A Phase III, multi-center, randomized (1:1), openlabel, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer Planned number of patients: 358 Participating groups: GINECO, NSGO, NCRI, CEEGOG, AGO, A-AGO, MITO, MaNGO and BGOG ENGOT-ov60/NCRI/GOG-3052/RAMP201 Leading group: NCRI Clinical Trial Study: A phase II trial of VS-6766 monotherapy and in combination with Defactinib in recurrent Low Grade Serous Ovarian Cancer Planned number of patients: 116 Participating groups: NCRI GOG partners, GEICO, BGOG, GINECO, MaNGO, Princess Margaret Consortium Canada ENGOT-ov59/NOGGO/MAMOC Leading group: NOGGO Clinical Trial Study: Rucaparib MAintenance after Bevacizumab Maintenance following Carboplatin based first line chemotherapy in Ovarian Cancer patients Planned number of patients: 190 Participating groups: AGO ENGOT-ov58/GINECO/TEDOVA Leading group: GINECO Clinical trial Study: Neoepitope vaccine (TEDOPI) in combination with pembolizumab as maintenance treatment for ovarian cancer in platinum sensitive relapse Planned number of patients: 360 Participating groups: AGO, BGOG ENGOT-ov57/AGO Leading group: AGO Clinical Trial Study: Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemother-apy in advanced ovarian cancer Planned number of patients: 970 Participating groups: BGOG, CEEGOG, GEICO, MANGO ENGOT-ov56/NSGO-CTU/DOVACC Leading group: NSGO-CTU Clinical Trial Study: A three-arm randomized study of olaparib, durvalumab and UV1 as maintenance therapy in BRCAwt patients in with relapsed ovarian cancer where platatinum combination therapy is an option Planned number of patients: 184 Participating groups: BGOG, NOGGO, HeCOG, DGOG, A-AGO ENGOT-ov55/BGOG/MIRASOL Leading group: BGOG Clinical trial Study: MIRASOL: A phase 3 registration trial for Mirvetuximab-Soravtansine using PS2+ scoring in FRα high platinum resistant ovarian cancer patients Planned number of patients: 430 Participating groups: GEICO, DGOG, CEEGOG, ISGO, PGOG, MANGO, NCRI, AGO, GINECO ENGOT-ov54/Swiss-GO/MATAO Leading group: Swiss-GO Clinical Trial Study: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a Randomized Double-blinded Placebo-controlled Phase III Trial Planned number of patients: 540 Participating groups: AGO, A-AGO ENGOT-ov52/DGOG/OVHIPEC-2 Leading group: DGOG Clinical Trial Study: OVHIPEC-2 Randomized phase 3 trial comparing primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer Planned number of patients: 538 Participating groups: Cancer trials Ireland, ANZGOG, NSGO-CTU, MITO, GINECO, NCRI, USA (as guest member of the DGOG) ENGOT-ov51/MITO/NItCHE Leading group: MITO Clinical Trial Study: Randomized phase III trial on Niraparib-TSR 042 vs TSR 042 vs physician's choice chemotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for further platinum treatment Planned number of patients: 422 Participating groups: MaNGO, GINECO, HeCOG, CEEGOG, NOGGO ENGOT-ov49/MaNGO/NEWTON Leading group: MaNGO Clinical Trial Study: A multicenter, open-label phase II trial of customized dosing (Rapid Adjustment of Dose to reduce Adverse Reactions “RADAR” dosing) of niraparib as maintenance therapy in platinum sensitive ovarian, fallopian tube or primary peritoneal recurrent cancer patients. Planned number of patients: 105 Participating groups: NOGGO ENGOT-ov47-TR /NOGGO-AGO TR2/HELPER Leading group: NOGGO Clinical Trial Study: Prospective study of HE4 serum level in patients with first platinum sensitive relapsed ovarian cancer Planned number of patients: 500 Participating groups: A-AGO, AGO, BGOG, GEICO, MaNGO, MITO, NCRI ENGOT-ov45/NCRI/ATHENA Leading group: NCRI Clinical Trial Study: ATHENA - A multicenter, randomized, double-blind, placebo-controlled phase 3 study in ovarian cancer patients evaluating Rucaparib and Nivolumab as maintenance treatment following response to front-line Platinum-based chemotherapy Planned number of patients: 1000 Participating groups: AGO, BGOG, CEEGOG, CTI, GEICO, HeCOG, ISGO, MITO, NSGO, PGOG, TRSGO, (GOG Foundation Partners and other global groups) ENGOT-ov41/GEICO/ANITA Leading group: GEICO Clinical Trial Study: ANITA (Atezolizumab and NIraparib Treatment Association in recurrent ovarian cancer): A randomized phase III trial of platinum-based chemotherapy followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 Months Planned number of patients: 414 Participating groups: AGO, BGOG, GINECO, ISGO, MaNGO ENGOT-ov40/NOGGO/Expression VI Leading group: NOGGO Clinical Trial Study: Holistic Analysis of longterm survivors with ovarian cancer Planned number of patients: 100-200 per country Participating groups: A-AGO, BGOG, CEEGOG, GEICO, TRSGO, Swiss-GO, (Romania, PASGO) ENGOT-ov35/NCRI/ICON 9 Leading group: NCRI Clinical Trial Study: An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy Planned number of patients: 330 Participating groups: SGCTG (ANZGOG, NCIC), GCIG, Canadian cancer trials group ENGOT-ov34/AGO Ovar 2.29 Leading group: AGO Clinical Trial Study: Atezolizumab in combination with Bevacizumab +/- Chemotherapy versus Chemo-BEV standard in recurrent ovarian cancer – a randomised trial Planned number of patients: 664 Participating groups: A-AGO, BGOG, GEICO, GINECO, NSGO, SAKK, NSGO-CTU Next ENGOT meeting October 12-13, 2023 Leuven, Belgium Directly to: ESGO‘s Upcoming Conference eAcademy ENGOT Tutoring Collection ESGO‘s Journal latest articles myESGO ESGO Newsletter Get notified on all news and activities right in your mailbox. Sign-up Now! You May Also Like GCA WORKSHOPS Watch the Webcasts Read More CLINICAL TRIALS Latest Published Research Read More FOR PATIENTS Key Insights Read More ESGO 2023 Congress September 28 - October 1, 2023 Istanbul, Türkiye Read More